Wall Street brokerages predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will post ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for BioDelivery Sciences International’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.15). BioDelivery Sciences International posted earnings of ($0.29) per share in the same quarter last year, which would suggest a positive year over year growth rate of 58.6%. The firm is expected to issue its next earnings results on Thursday, March 21st.
On average, analysts expect that BioDelivery Sciences International will report full-year earnings of ($0.69) per share for the current year, with EPS estimates ranging from ($0.76) to ($0.56). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.52) to ($0.09). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. BioDelivery Sciences International had a negative net margin of 85.93% and a negative return on equity of 141.35%. The firm had revenue of $14.16 million for the quarter, compared to analyst estimates of $14.21 million.
In related news, Director Francis E. Odonnell, Jr. sold 151,039 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $2.84, for a total transaction of $428,950.76. Following the transaction, the director now directly owns 520,482 shares of the company’s stock, valued at $1,478,168.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the firm’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $3.84, for a total transaction of $30,720.00. Following the transaction, the director now directly owns 522,187 shares in the company, valued at $2,005,198.08. The disclosure for this sale can be found here. Insiders have sold 167,039 shares of company stock worth $481,671 over the last three months. 13.26% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of BDSI. Bank of Montreal Can purchased a new stake in BioDelivery Sciences International during the second quarter worth about $138,000. PNC Financial Services Group Inc. purchased a new stake in BioDelivery Sciences International during the second quarter worth about $148,000. Worth Venture Partners LLC purchased a new stake in BioDelivery Sciences International during the third quarter worth about $167,000. Dimensional Fund Advisors LP purchased a new stake in BioDelivery Sciences International during the third quarter worth about $255,000. Finally, Wells Fargo & Company MN increased its holdings in BioDelivery Sciences International by 121.7% during the third quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock worth $331,000 after buying an additional 64,803 shares during the last quarter. Institutional investors and hedge funds own 44.01% of the company’s stock.
Shares of BioDelivery Sciences International stock traded down $0.03 during trading hours on Friday, reaching $3.63. The company’s stock had a trading volume of 93,211 shares, compared to its average volume of 541,741. BioDelivery Sciences International has a one year low of $1.70 and a one year high of $4.14. The firm has a market capitalization of $256.67 million, a price-to-earnings ratio of -9.31 and a beta of 0.09. The company has a current ratio of 3.00, a quick ratio of 2.77 and a debt-to-equity ratio of 1.42.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Read More: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.